Hepatitis C research is among the fastest moving industry sectors as medications hailed as game-changes just two years ago are being trumped by newer therapeutics in the pipeline. Some physicians are telling HCV patients to wait for the newer drugs, while others say patients should be treated immediately with what is already available.
Rival hepatitis C drugs from Merck & Co and Vertex Pharmaceuticals are effective in patients also infected with HIV, the virus that causes AIDS, according to data released on Tuesday. The Vertex drug had the more impressive results, the data showed.
The dust is starting to settle following FDA’s approval last month of Merck’s Victrelis (boceprevir) and Incivek (telaprevir) by Vertex – the two new breakthrough protease inhibitors for hepatitis C. Read more in the Specialty Pharma Journal